Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: cyclophosphamideDrug: cyclosporineDrug: fludarabine phosphateDrug: gemcitabine hydrochlorideDrug: ifosfamideDrug: mechlorethamine hydrochlorideDrug: melphalanDrug: methotrexateDrug: mycophenolate mofetilDrug: prednisoneDrug: procarbazine hydrochlorideDrug: vincristine sulfateDrug: vinorelbine tartrateProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: total-body irradiation
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00574496
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
- Conditions
- Waldenström MacroglobulinemiaLymphoplasmacytic LymphomaSplenic Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- French Study Group on Chronic Lymphoid Leukemia
- Target Recruit Count
- 414
- Registration Number
- NCT00566332
- Locations
- 🇫🇷
Hôpital La Pitié-Salpêtrière. 47-83 Bd de l'hôpital, Paris, France
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
- Conditions
- Hodgkin LymphomaJuvenile Myelomonocytic Leukemia (JMML)Lymphoma, Non-Hodgkin (NHL)Leukemia, Acute Lymphocytic (ALL)Leukemia, Myeloid, Acute(AML)Leukemia, Myeloid, Chronic(CML)Hemoglobinuria, Paroxysmal Nocturnal (PNH)Myelodysplastic Syndrome (MDS)
- Interventions
- Device: CliniMACSProcedure: Stem cell transplantationDrug: FludarabineDrug: Thioplex®Drug: L-phenylalanine mustardDrug: Mycophenolate mofetilDrug: Rituxan™Drug: AlemtuzumabDrug: CyclophosphamideDrug: Anti-thymocyte globulin (Rabbit)Drug: G-CSFDrug: Muromonab
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT00566696
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response
- Conditions
- B-cell Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 10
- Registration Number
- NCT00565981
- Locations
- 🇦🇹
Universitätsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck, Austria
🇦🇹A.ö. Landeskrankenhaus Fürstenfeld, Fürstenfeld, Austria
🇦🇹St. Johanns LK, Salzburg, Austria
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 178
- Registration Number
- NCT00564512
- Locations
- 🇫🇷
Centre Henri Becquerel, Rouen, France
MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning
- Conditions
- Multiple Myeloma
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT00564200
- Locations
- 🇪🇸
H. de Jerez, Jerez de la Frontera, Spain
🇪🇸Instituto Catalán de Oncología, Barcelona, Spain
🇪🇸H. 12 de Octubre, Madrid, Spain
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Lymphoma, Follicular
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00562965
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
🇺🇸Facey Medical Group, Mission Hills, California, United States
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
- Conditions
- Non-Cancer DiagnosisImmunodeficiency Syndrome
- Interventions
- Biological: AlemtuzumabProcedure: Allogeneic Bone Marrow TransplantationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclosporineDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: Mycophenolate MofetilRadiation: Total-Body Irradiation
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00553098
- Locations
- 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
- Conditions
- LeukemiaLymphoma
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- CTI BioPharma
- Registration Number
- NCT00551239
- Locations
- 🇺🇸
Cell Therapeutics, Incorporated, Seattle, Washington, United States
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
- Conditions
- LeukemiaLymphomaMyelodysplastic Syndromes
- Interventions
- Biological: filgrastimDrug: CyclophosphamideDrug: BusulfanDrug: CyclosporineDrug: Fludarabine phosphateDrug: Mycophenolate MofetilDrug: MelphalanProcedure: allogeneic hematopoietic stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: Fractionated total body irradiationRadiation: total-body irradiation
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00547196
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.